These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7896048)

  • 1. Synergistic antiplatelet effects of a nipecotamide A-1C and low dose aspirin.
    Han G; Bond SE; Lawrence WH; Dillingham EO; Zheng X; Gollamudi R
    Gen Pharmacol; 1994 Nov; 25(7):1373-9. PubMed ID: 7896048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet effects of R,S-(meso)-alpha, alpha'-bis[3-(N,N-diethylcarbamoyl) piperidino]-p-xylene ex vivo in the dog and in vivo in the mouse.
    Han G; Bannerman D; Handa RK; Dillingham EO; Lawrence WH; Gollamudi R
    Gen Pharmacol; 1997 Apr; 28(4):617-21. PubMed ID: 9147034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet activity of nipecotamides in experimental thrombosis in mice.
    Lawrence WH; Howell RD; Gollamudi R
    J Pharm Sci; 1994 Feb; 83(2):222-5. PubMed ID: 8169794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activities of the novel antiplatelet agent alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide.
    Lyman BA; Bond SE; Dillingham EO; Lawrence WH; Gollamudi R
    Res Commun Chem Pathol Pharmacol; 1992 Dec; 78(3):279-88. PubMed ID: 1475529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enantioselective antiplatelet actions of nipecotamides.
    Gollamudi R; Feng Z; Dillingham EO; Bond SE; Han G; Salgia S
    Thromb Res; 1993 Feb; 69(4):361-7. PubMed ID: 8470057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity.
    Han BH; Suh DY; Yang HO; Park YH; Kang YH; Kim YC
    Arzneimittelforschung; 1994 Oct; 44(10):1122-6. PubMed ID: 7818584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic activity of methanolic extract of Umbilicaria esculenta.
    Kim MS; Lee KA
    J Ethnopharmacol; 2006 May; 105(3):342-5. PubMed ID: 16384677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of the combination of aspirin and nifedipine on platelet aggregation and thrombogenesis].
    Dong E; Shi S
    Zhonghua Xin Xue Guan Bing Za Zhi; 1990 Oct; 18(5):301-3, 319. PubMed ID: 2086198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of diltiazem and low-dose aspirin on platelet aggregation and ATP release induced by paired agonists.
    Zucker ML; Budd SE; Dollar LE; Chernoff SB; Altman R
    Thromb Haemost; 1993 Aug; 70(2):332-5. PubMed ID: 8236144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.
    Vanags DM; Rodgers SE; Duncan EM; Lloyd JV; Bochner F
    Br J Pharmacol; 1992 Aug; 106(4):917-23. PubMed ID: 1393289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate.
    Kang WS; Lim IH; Yuk DY; Chung KH; Park JB; Yoo HS; Yun YP
    Thromb Res; 1999 Nov; 96(3):229-37. PubMed ID: 10588466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic nipecotamide increases cyclic AMP levels and inhibits protein phosphorylation in human platelets.
    Handa RK; Dillingham EO; Gollamudi R
    Life Sci; 1995; 57(10):983-8. PubMed ID: 7643723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.
    Celestini A; Pulcinelli FM; Pignatelli P; Lenti L; Frati G; Gazzaniga PP; Violi F
    Haematologica; 2002 Apr; 87(4):420-6. PubMed ID: 11940487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative.
    Jin YR; Hwang KA; Cho MR; Kim SY; Kim JH; Ryu CK; Son DJ; Park YH; Yun YP
    Vascul Pharmacol; 2004 Feb; 41(1):35-41. PubMed ID: 15135330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why single daily dose of aspirin may not prevent platelet aggregation.
    Altman R; Scazziota A; Funes JC
    Thromb Res; 1988 Aug; 51(3):259-66. PubMed ID: 3140408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation.
    Odawara A; Kikkawa K; Katoh M; Toryu H; Shimazaki T; Sasaki Y
    Circ Res; 1996 Apr; 78(4):643-9. PubMed ID: 8635222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals.
    Momo K; Someya K; Tachiiri T; Mitsuoka Y; Nakamura K; Imai S; Ino T; Ohkubo H
    Arzneimittelforschung; 1992 Jan; 42(1):32-9. PubMed ID: 1586377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.